PRESS RELEASE published on 04/27/2023 at 07:30, 3 years 3 months ago Formycon publishes results for financial year 2022
PRESS RELEASE published on 04/25/2023 at 07:00, 3 years 3 months ago Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
PRESS RELEASE published on 02/07/2023 at 07:30, 3 years 6 months ago Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG
PRESS RELEASE published on 02/06/2023 at 07:30, 3 years 6 months ago Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study
PRESS RELEASE published on 02/02/2023 at 08:00, 3 years 6 months ago Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
PRESS RELEASE published on 02/02/2023 at 07:30, 3 years 6 months ago EQS-Adhoc: Formycon AG announces result of private placement and sets placement price for the new shares from the capital increase
PRESS RELEASE published on 02/01/2023 at 23:30, 3 years 6 months ago EQS-Adhoc: Formycon AG upsizes capital increase from authorized capital following strong demand
PRESS RELEASE published on 02/01/2023 at 17:40, 3 years 6 months ago EQS-Adhoc: Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
PRESS RELEASE published on 02/01/2023 at 17:40, 3 years 6 months ago EQS-Adhoc: Formycon AG plans capital increase of approx. 5% of the share capital by way of an accelerated bookbuilding procedure to finance further growth
PRESS RELEASE published on 01/09/2023 at 13:05, 3 years 7 months ago EQS-Adhoc: Formycon announces binding Term Sheet between Klinge Biopharma and Coherus BioSciences for the exclusive commercialization of FYB203, a biosimilar candidate to Eylea®1, in the United States
Published on 08/17/2026 at 12:40, 25 minutes ago BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
Published on 08/17/2026 at 12:00, 1 hour 5 minutes ago Banyan Gold Intersects 13.03 g/t Au Over 14.2m at Powerline North, AurMac, Yukon, Canada
Published on 08/17/2026 at 12:00, 1 hour 5 minutes ago NuRAN Wireless Announces Nasdaq Listing and West African US$ 5M Project Kickoff for State-Owned Mobile Operator
Published on 08/17/2026 at 09:10, 3 hours 55 minutes ago HM Exploration Commences Borehole & Surface EM Surveys at Lewis Pilley's
Published on 08/17/2026 at 12:33, 31 minutes ago EQS-Adhoc: fox e-mobility AG: Clean Auditor's Certificate for Annual Financial Statements 2023
Published on 08/17/2026 at 11:55, 1 hour 10 minutes ago Taiwan Weeks 2026 set for Nov. 3-13 with expanded international participation
Published on 08/17/2026 at 11:00, 2 hours 4 minutes ago Turkiye Garanti Bankasi A.S.: Issuance of Green/Sustainable Tier- 2 Eurobond Abroad
Published on 08/17/2026 at 09:59, 3 hours 6 minutes ago 260817 BENETEAU Transaction sur actions propres
Published on 08/17/2026 at 08:33, 4 hours 32 minutes ago Covivio - Information on Treasury shares transactions between August 10th, 2026 and August 11th, 2026
Published on 08/17/2026 at 08:33, 4 hours 32 minutes ago Covivio - Déclaration des transactions sur actions propres réalisées du 10 août 2026 au 11 août 2026
Published on 08/17/2026 at 07:30, 5 hours 35 minutes ago Déclaration hebdomadaire d'opérations effectuées du 10 au 14 août 2026
Published on 08/17/2026 at 07:30, 5 hours 35 minutes ago Disclosure of transactions in own shares from August 10 to August 14, 2026
